Role of Inflammatory Markers in Sepsis

Recruiting

• Conditions: Diagnostic
• Interventions: Diagnostic Test: Serology tests

• Registration Number: NCT06111963
• Lead Sponsor: National Cancer Institute, Egypt

Brief Summary

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-10-16
• Study First Submitted QC: 2023-10-26
• Study Start: 2023-11-01
• Study First Posted: 2023-11-01
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-17
• Last Update Posted: 2024-01-18
• Primary Completion: 2024-07
• Study Completion: 2024-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis

Exclusion Criteria

• Refusal of patient or patient guardian to participate.
• Intraoperative massive blood loss and massive blood transfusion
• Patients with impaired preoperative kidney or liver function tests

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Septic patients	Serology tests	-
Non Septic patients	Serology tests	-

Primary Outcome Measures

Name	Time	Method
To evaluate the expression CD4	7 days	Serology
To evaluate the expression IL17	7 days	Serology
To evaluate the expression CD25	7 days	Serology

Trial Locations

Locations (1)

Walaa Y Elsabeeny; 🇪🇬 Cairo, Egypt